2026-04-14T07:09:03Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/128872025-05-04T02:55:36Zcom_2072_378070com_2072_378040col_2072_378092

STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma Pal, Sumanta Kanesvaran, Ravindran Molina-Cerrillo, Javier Feldman, Darren Barata, Pedro Powles, Thomas Suárez, Cristina Institut Català de la Salut [Pal SA] Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. [Powles T] Department of Genitourinary Oncology, Barts Health NHS Trust Saint Bartholomew’s Hospital, London, UK. [Kanesvaran R] Division of Medical Oncology, National Cancer Centre Singapore, Singapore. [Molina-Cerrillo J] Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Feldman DR] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [Barata P] Department of Medicine, University Hospitals Seidman Cancer Center, Cleveland, OH, USA. [Suarez C] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Ronyons - Càncer - Tractament Quimioteràpia combinada Anticossos monoclonals - Ús terapèutic Proteïnes quinases - Inhibidors - Ús terapèutic ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols DISEASES::Neoplasms::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Urologic Neoplasms::Kidney Neoplasms::Carcinoma, Renal Cell CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors Other subheadings::Other subheadings::Other subheadings::/antagonists & inhibitors CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal Other subheadings::Other subheadings::/therapeutic use DISEASES::Neoplasms::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Urologic Neoplasms::Kidney Neoplasms::Carcinoma, Renal Cell Other subheadings::Other subheadings::Other subheadings::/drug therapy TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas Otros calificadores::Otros calificadores::Otros calificadores::/antagonistas & inhibidores COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales Otros calificadores::Otros calificadores::/uso terapéutico ENFERMEDADES::neoplasias::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias urológicas::neoplasias renales::carcinoma de células renales Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia Immune checkpoint inhibitor; Non-clear cell renal cell carcinoma; Tyrosine kinase inhibitor Inhibidor del punt de control immunitari; Carcinoma renal de cèl·lules no clares; Inhibidor de la tirosina cinasa Inhibidor del punto de control inmunitario; Carcinoma renal de células no claras; Inhibidor de la tirosina quinasa Management of advanced non-clear cell renal cell carcinoma (nccRCC) is challenging due to disease rarity and heterogeneity. The combination of multi-targeted tyrosine kinase inhibitor (TKI) with immune checkpoint inhibitor (ICI) has emerged as an effective treatment strategy, but well-designed, phase III randomized clinical trials are needed to demonstrate superiority over current treatment options. Zanzalintinib is a novel, multi-targeted TKI that has demonstrated promising preclinical anti-tumor activity in combination with ICIs. STELLAR-304 is a phase III trial evaluating first-line zanzalintinib plus nivolumab versus sunitinib in advanced nccRCC. Primary endpoints are progression-free survival and objective response rate. Secondary endpoint is overall survival. To our knowledge, STELLAR-304 is the first phase III study assessing a TKI-ICI combination in nccRCC patients across multiple subtypes. STELLAR-304 is sponsored by Exelixis, Inc. (Alameda, CA, USA). 2025-04-02T12:56:24Z 2025-04-02T12:56:24Z 2025-02-26 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Pal SK, Powles T, Kanesvaran R, Molina-Cerrillo J, Feldman DR, Barata P, et al. STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma. Futur Oncol. 2025 Feb 26;21(7):787-94. 1744-8301 http://hdl.handle.net/11351/12887 10.1080/14796694.2025.2458395 40008409 001433380500001 eng Future Oncology;21(7) https://doi.org/10.1080/14796694.2025.2458395 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess application/pdf Taylor & Francis Scientia